89 research outputs found
Comparison of urinary excretion of total polyphenols after a high antioxidant diet and a low antioxidant diet
Podeu consultar el III Workshop anual INSA-UB complet a: http://hdl.handle.net/2445/118993Sessió 1. Pòster
Mediterranean Diet and atherothrombosis biomarkers: a randomized controlled trial
Scope. To assess whether following a Mediterranean diet (MedDiet) improved
atherothrombosis biomarkers in high cardiovascular risk individuals.
Methods and results. In 358 random volunteers from the PREvención con DIeta MEDiterránea trial, we assessed the 1-year effects on atherothrombosis markers of an
intervention with MedDiet, enriched with virgin olive oil (MedDiet-VOO; n=120) or nuts
(MedDiet-Nuts; n=119) versus a low-fat control diet (n=119). We also studied whether large increments in MedDiet adherence (≥3 score points, relative to compliance
decreases) and intake changes in key food items were associated with 1-year differences
in biomarkers. We observed differences between 1-year changes in the MedDiet-VOO intervention and control diet on the activity of platelet activating factor acetylhydrolase in
HDLs (+7.5% [95% confidence interval: 0.17; 14.8]) and HDL-bound α1-antitrypsin levels (-
6.1% [-11.8; -0.29]), and between the MedDiet-Nuts intervention and the control arm on non-esterified fatty acid concentrations (-9.3% [-18.1; -0.53]). Large MedDiet adherence
increments were associated with less fibrinogen (-9.5% [-18.3; -0.60]) and non-esterified fatty acid concentrations (-16.7% [-31.7; -1.74]). Increases in nut, fruit, vegetable, and fatty
fish consumption, and decreases in processed meat intake were linked to beneficial changes in atherothrombosis biomarkers.
Conclusion. Following a MedDiet improved atherothrombosis biomarkers in high cardiovascular risk individual
MRI compared to conventional diagnostic work-up in the detection and evaluation of invasive lobular carcinoma of the breast: a review of existing literature
Item does not contain fulltextPURPOSE: The clinical diagnosis and management of invasive lobular carcinoma (ILC) of the breast presents difficulties. Magnetic resonance imaging (MRI) has been proposed as the imaging modality of choice for the evaluation of ILC. Small studies addressing different aspects of MRI in ILC have been presented but no large series to date. To address the usefulness of MRI in the work-up of ILC, we performed a review of the currently published literature. MATERIALS AND METHODS: We performed a literature search using the query "lobular AND (MRI OR MR OR MRT OR magnetic)" in the Cochrane library, PubMed and scholar.google.com, to retrieve all articles that dealt with the use of MRI in patients with ILC. We addressed sensitivity, morphologic appearance, correlation with pathology, detection of additional lesions, and impact of MRI on surgery as different endpoints. Whenever possible we performed meta-analysis of the pooled data. RESULTS: Sensitivity is 93.3% and equal to overall sensitivity of MRI for malignancy in the breast. Morphologic appearance is highly heterogeneous and probably heavily influenced by interreader variability. Correlation with pathology ranges from 0.81 to 0.97; overestimation of lesion size occurs but is rare. In 32% of patients, additional ipsilateral lesions are detected and in 7% contralateral lesions are only detected by MRI. Consequently, MRI induces change in surgical management in 28.3% of cases. CONCLUSION: This analysis indicates MRI to be valuable in the work-up of ILC. It provides additional knowledge that cannot be obtained by conventional imaging modalities which can be helpful in patient treatment
Polyphenol intake and mortality risk: a re-analysis of the PREDIMED trial
Background: Polyphenols may lower the risk of cardiovascular disease (CVD) and other chronic diseases due to
their antioxidant and anti-inflammatory properties, as well as their beneficial effects on blood pressure, lipids and
insulin resistance. However, no previous epidemiological studies have evaluated the relationship between the intake
of total polyphenols intake and polyphenol subclasses with overall mortality. Our aim was to evaluate whether
polyphenol intake is associated with all-cause mortality in subjects at high cardiovascular risk.
Methods: We used data from the PREDIMED study, a 7,447-participant, parallel-group, randomized, multicenter,
controlled five-year feeding trial aimed at assessing the effects of the Mediterranean Diet in primary prevention of
cardiovascular disease. Polyphenol intake was calculated by matching food consumption data from repeated food
frequency questionnaires (FFQ) with the Phenol-Explorer database on the polyphenol content of each reported
food. Hazard ratios (HR) and 95% confidence intervals (CI) between polyphenol intake and mortality were estimated
using time-dependent Cox proportional hazard models.
Results: Over an average of 4.8 years of follow-up, we observed 327 deaths. After multivariate adjustment, we
found a 37% relative reduction in all-cause mortality comparing the highest versus the lowest quintiles of total
polyphenol intake (hazard ratio (HR) = 0.63; 95% CI 0.41 to 0.97; P for trend = 0.12). Among the polyphenol subclasses,
stilbenes and lignans were significantly associated with reduced all-cause mortality (HR =0.48; 95% CI 0.25 to 0.91; P for
trend = 0.04 and HR = 0.60; 95% CI 0.37 to 0.97; P for trend = 0.03, respectively), with no significant associations apparent
in the rest (flavonoids or phenolic acids).
Conclusions: Among high-risk subjects, those who reported a high polyphenol intake, especially of stilbenes and
lignans, showed a reduced risk of overall mortality compared to those with lower intakes. These results may be useful
to determine optimal polyphenol intake or specific food sources of polyphenols that may reduce the risk of all-cause
mortality.
Clinical trial registration: ISRCTN35739639
Recommended from our members
Dietary α‐Linolenic Acid, Marine ω‐3 Fatty Acids, and Mortality in a Population With High Fish Consumption: Findings From the PREvención con DIeta MEDiterránea (PREDIMED) Study
Background: Epidemiological evidence suggests a cardioprotective role of α‐linolenic acid (ALA), a plant‐derived ω‐3 fatty acid. It is unclear whether ALA is beneficial in a background of high marine ω‐3 fatty acids (long‐chain n‐3 polyunsaturated fatty acids) intake. In persons at high cardiovascular risk from Spain, a country in which fish consumption is customarily high, we investigated whether meeting the International Society for the Study of Fatty Acids and Lipids recommendation for dietary ALA (0.7% of total energy) at baseline was related to all‐cause and cardiovascular disease mortality. We also examined the effect of meeting the society's recommendation for long‐chain n‐3 polyunsaturated fatty acids (≥500 mg/day). Methods and Results: We longitudinally evaluated 7202 participants in the PREvención con DIeta MEDiterránea (PREDIMED) trial. Multivariable‐adjusted Cox regression models were fitted to estimate hazard ratios. ALA intake correlated to walnut consumption (r=0.94). During a 5.9‐y follow‐up, 431 deaths occurred (104 cardiovascular disease, 55 coronary heart disease, 32 sudden cardiac death, 25 stroke). The hazard ratios for meeting ALA recommendation (n=1615, 22.4%) were 0.72 (95% CI 0.56–0.92) for all‐cause mortality and 0.95 (95% CI 0.58–1.57) for fatal cardiovascular disease. The hazard ratios for meeting the recommendation for long‐chain n‐3 polyunsaturated fatty acids (n=5452, 75.7%) were 0.84 (95% CI 0.67–1.05) for all‐cause mortality, 0.61 (95% CI 0.39–0.96) for fatal cardiovascular disease, 0.54 (95% CI 0.29–0.99) for fatal coronary heart disease, and 0.49 (95% CI 0.22–1.01) for sudden cardiac death. The highest reduction in all‐cause mortality occurred in participants meeting both recommendations (hazard ratio 0.63 [95% CI 0.45–0.87]). Conclusions: In participants without prior cardiovascular disease and high fish consumption, dietary ALA, supplied mainly by walnuts and olive oil, relates inversely to all‐cause mortality, whereas protection from cardiac mortality is limited to fish‐derived long‐chain n‐3 polyunsaturated fatty acids. Clinical Trial Registration URL: http://www.Controlled-trials.com/. Unique identifier: ISRCTN35739639
- …